Previous 10 | Next 10 |
The following slide deck was published by Curis, Inc. in conjunction with this event. For further details see: Curis (CRIS) Investor Presentation - Slideshow
Curis to Present at Upcoming Healthcare Conferences in September PR Newswire LEXINGTON, Mass. , Sept. 7, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment ...
Curis ( NASDAQ: CRIS ) said the U.S. Food and Drug Administration (FDA) allowed patient enrollment to resume in the monotherapy phase of the TakeAim Leukemia study. Earlier in August, the FDA had lifted a partial clinical hold on a phase 1/2 trial (TakeAim Lymphoma) ...
FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study PR Newswire Curis working with clinical sites to resume enrollment Preliminary clinical data update expected in 2023 LEXINGTON, Mass. ,...
Gainers: Cedar Realty Trust ( CDR ) +207% . Neptune Wellness Solutions ( NEPT ) +122% . Edible Garden AG Incorporated ( EDBL ) +57% . Indonesia Energy Corporation ( INDO ) +37% . Hillstream BioPharma ( HILS ) +30% . Mind Medi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: rafapress / Shutterstock Bluebird Bio (NASDAQ: BLUE ) stock is on the move Thursday following U.S. Food and Drug Administration (FDA) approval for ZYNTEGLO . ZYNTEGLO is a gene therapy designed for pa...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Gorodenkoff / Shutterstock.com Today is a big day for biotech firm Curis (NASDAQ: CRIS ) and CRIS stock. The U.S. Food and Drug Administration (FDA) just completed its review of the company’s Take...
Gainers: Curis ( CRIS ) +36% . Allarity Therapeutics ( ALLR ) +23% . Codiak BioSciences ( CDAK ) +21% . Cassava Sciences ( SAVA ) +17% . AlerisLife ( ALR ) +11% . Losers: Blue Water Vaccines ( BWV ) -27% ...
Curis ( NASDAQ: CRIS ) said the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on a phase 1/2 trial (TakeAim Lymphoma) of emavusertib in lymphoma after reviewing data submitted by the company. In April, the FDA placed separate partial clinic...
FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib PR Newswire Curis working with clinical sites to resume enrollment Preliminary clinical data update expected in 2023 LEXINGTON, Mass. , Aug. 18, 2022 /PRNewswire/...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis to Present at Upcoming Healthcare Conference in July PR Newswire LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IR...
2024-05-25 08:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...